Research output per year
Research output per year
Personal profile
Education/Academic qualification
Organic Chemistry, Doctor of Science, Synthetic Studies Towards Thysanone, a 3C Protease Inhibitor of the Human Rhinovirus, University of Sydney
… → 2000
Award Date: 1 Feb 2001
Science, Bachelor of Science
… → 1995
External positions
Drug Discovery Officer, Children's Cancer Institute Australia
Mar 2015 → Nov 2015
Senior Scientific Officer, Institute of Cancer Research
Oct 2007 → Nov 2014
Higher Scientific Officer, Institute of Cancer Research
Jul 2001 → Oct 2007
Fingerprint
Dive into the research topics where Richard Elliott is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
High throughput screening identifies activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma
Danks, M., Manasterski, P., Beetham, H., Dawson, J. C., Elliott, R., Culley, J., Krishna, R., Muir, M. T., Thomson, J. P., Oswald, A., Ewing, A., Kerrison, W. G. J., Huang, P. H., Nixon, I., Carragher, N. O. & Brunton, V. G., 10 Nov 2025, (Accepted/In press) In: Cancer Biology & Therapy.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Drug Combinations Targeting FAK and MEK Overcomes 2 Tumour Heterogeneity in Glioblastoma
Furqan, M., Elliott, R., Nagle, P., Dawson, J. C., Masalmeh, R., Alvarez Garcia, V., Munro, A., Drake, C., Morrison, G., Pollard, S. M., Ebner, D., Brunton, V. G., Frame, M. C. & Carragher, N. O., 23 Apr 2025, (E-pub ahead of print) In: Pharmaceutics.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Cellular activity of CQWW nullomer-derived peptides
Shave, S., Isaksson, R., Pham, N. T., Elliott, R. J. R., Dawson, J. C., Soudant, J., Carragher, N. O. & Auer, M., 25 Feb 2025, In: ACS Omega. 10, 7, p. 6794-6800 20 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
P26.01.B A PHARMACOLOGICAL SURVEY ACROSS GLIOMA STEM CELL PHENOTYPES REVEAL NOVEL GLIOBLASTOMA DRUG-TARGETS, DRUG REPURPOSING OPPORTUNITIES AND FUTURE DRUG COMBINATION STRATEGIES
Elliott, R., Furqan, M., Nagle, P., Munro, A., Drake, C., Dawson, J. C., Brunton, V., Frame, M. & Carragher, N. O., 17 Oct 2024, In: Neuro-Oncology. 26, Supplement_5, p. v132-v132Research output: Contribution to journal › Meeting abstract › peer-review
-
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
Hollis, R., Elliott, R., Dawson, J. C., Ilenkovan, N., Matthews, R., Stillie, L., Oswald, A., Kim, H., Llaurado Fernandez, M., Churchman, M., Porter, J. C., Roxburgh, P., Unciti-Broceta, A., M Gershenson, D., Herrington, C. S., S Carey, M., Carragher, N. O. & Gourley, C., 5 Apr 2024, In: Gynecologic Oncology. 186, p. 42-52Research output: Contribution to journal › Article › peer-review
Open AccessFile
Projects
- 1 Finished
-
Preliminary screen for compounds targeting phenotypic deficits associated with deletion of SORL1 in a human neural cell-based model
Evans, K. (Principal Investigator), Carragher, N. (Co-investigator), Dawson, J. (Co-investigator), Elliott, R. (Co-investigator) & McDiarmid, A. (Co-investigator)
1/07/21 → 30/06/22
Project: Research
Datasets
-
High Content Drug Screening & Analysis Dataset: A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models
Elliott, R. (Creator) & Carragher, N. (Creator), Edinburgh DataShare, 28 Jul 2026
DOI: 10.7488/ds/8038, https://www.biorxiv.org/content/10.1101/2024.11.27.625719v3
Dataset